Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 in Healthy Volunteers
NCT04640831Phase 1Completed
- Sponsor
- GH Research PLC
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of mebufotenin in treatment-resistant depression (TRD) (5 arms), sponsored by GH Research PLC. Primary endpoints: Safety and tolerability of GH001 at 7 days and Dose-related psychoactive effects at 3 hours. Started Mar 2019; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04640831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640831.